Deal of the Day — limited-time pharmacy picks!
Erbitux 100mg Injection

Erbitux 100mg Injection

Prescription requiredRx Required

Salt Composition: Cetuximab Injection

Expiry Date: 01/2028

Special offer

Buy at $1,250.00

$1,250.00

Inclusive of all taxes

▼

1 Vial(s) Of 100ml

About The Product

colon and rectum cancer

Description

Erbitux 100mg Injection is an antineoplastic injection prescribed by the doctor to treat certain types of cancer, primarily squamous cell carcinoma of the head and neck (SCCHN) and colorectal cancer expressing EGFR. Erbitux 100mg Injection contains Cetuximab monoclonal antibody that specifically binds to the Endothelial Growth Factor Receptor that is responsible for blood vessel formation to supply nutrients to cancer cells.

Blockage of EGFR leads to cancer cell growth inhibition.

Dosage And Administration

  • Erbitux 100mg Injection is administered intravenously (In Veins) by a doctor or an experienced nurse.
  • It is advice not to self administer the injection on your own.
  • For personalized dosage ask your doctor about the same.
  • As Dosage is entirely based on the body surface area, type of cancer, its stage as well as patient's overall health.

Mechanism Of Action

Erbitux 100mg Injection contains Cetuximab monoclonal antibody that specifically binds to the Endothelial Growth Factor Receptor that inhibits receptor activation by natural ligands like EGF and blocking signaling pathways that facilitate tumour survival, proliferation, and metastasis. This action leads to reduced tumour growth, increased apoptosis, and enhanced sensitivity to therapies.

Additionally, it promotes EGFR down-regulation and recruits immune cells for targeted cytotoxicity against tumours.

Faqs

Erbitux 100mg Injection is used to treat certain types of cancer, primarily squamous cell carcinoma of the head and neck (SCCHN) and colorectal cancer expressing EGFR .

References

• Vincenzi, B., Schiavon, G., Silletta, M., Santini, D., & Tonini, G. (2008).

The biological properties of cetuximab. Critical reviews in oncology/hematology, 68(2), 93-106. • Jonker, D.

J., O'Callaghan, C. J., Karapetis, C.

S., Zalcberg, J. R., Tu, D., Au, H.

J., ... & Moore, M. J.

(2007). Cetuximab for the treatment of colorectal cancer.

New England Journal of Medicine, 357(20), 2040-2048. • Bou-Assaly, W., & Mukherji, S. (2010).

Cetuximab (erbitux). American Journal of Neuroradiology, 31(4), 626-627. • Ocvirk, J., & Cencelj, S.

(2010). Management of cutaneous side‐effects of cetuximab therapy in patients with metastatic colorectal cancer.

Journal of the European Academy of Dermatology and Venereology, 24(4), 453-459.

Certified Content

Written By
Venika Choudhary

Venika Choudhary

Medical Content Writer @ Magicine Pharma

Reviewed By
Dr. Aditya Sarin

Dr. Aditya Sarin

MBBS, MD - General Medicine, DrNB - Medical Oncology | 11 Years Experience

Check Our Editorial Policy

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026